Stuttgart - Delayed Quote EUR
KES/USD (AXD2.SG)
1.8770
-0.1200
(-6.01%)
At close: May 6 at 8:00:48 AM GMT+2
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Total Revenue
144.28M
144.28M
127.04M
107.67M
86.35M
Cost of Revenue
38.65M
38.65M
65.11M
54.87M
46.02M
Gross Profit
105.64M
105.64M
61.94M
52.80M
40.33M
Operating Expense
117.17M
117.17M
172.55M
227.46M
258.15M
Operating Income
-11.53M
-11.53M
-110.61M
-174.66M
-217.83M
Net Non Operating Interest Income Expense
-2.48M
-2.48M
-504.00k
-836.00k
-1.98M
Other Income Expense
430.00k
430.00k
560.00k
-6.53M
-878.00k
Pretax Income
-13.58M
-13.58M
-110.56M
-182.02M
-220.68M
Net Income Common Stockholders
-13.58M
-13.58M
-110.56M
-182.02M
-220.68M
Diluted NI Available to Com Stockholders
-13.58M
-13.58M
-110.56M
-182.02M
-220.68M
Basic EPS
-0.16
--
-0.80
-1.67
-2.24
Diluted EPS
-0.16
--
-0.80
-1.67
-2.24
Basic Average Shares
151.98M
--
138.13M
109.00M
98.47M
Diluted Average Shares
151.98M
--
138.13M
109.00M
98.47M
Total Operating Income as Reported
-11.53M
-11.53M
-110.61M
-174.66M
-217.83M
Total Expenses
155.81M
155.81M
237.66M
282.33M
304.17M
Net Income from Continuing & Discontinued Operation
-13.58M
-13.58M
-110.56M
-182.02M
-220.68M
Normalized Income
-13.58M
-13.58M
-110.56M
-182.02M
-220.68M
Interest Income
3.55M
3.55M
3.36M
1.64M
433.00k
Interest Expense
6.03M
6.03M
3.87M
2.47M
2.41M
Net Interest Income
-2.48M
-2.48M
-504.00k
-836.00k
-1.98M
EBIT
-7.55M
-7.55M
-106.69M
-179.55M
-218.27M
EBITDA
-5.06M
-5.06M
-103.79M
-176.66M
-215.25M
Reconciled Cost of Revenue
38.65M
38.65M
65.11M
54.87M
46.02M
Reconciled Depreciation
2.49M
2.49M
2.90M
2.89M
3.02M
Net Income from Continuing Operation Net Minority Interest
-13.58M
-13.58M
-110.56M
-182.02M
-220.68M
Normalized EBITDA
-5.06M
-5.06M
-103.79M
-176.66M
-215.25M
Tax Rate for Calcs
0.00
0.00
0.00
0.00
0.00
Tax Effect of Unusual Items
0.00
0.00
0.00
0.00
0.00
12/31/2021 - 6/23/2015
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
IKAP.DU Aurinia Pharmaceuticals Inc
7.08
-1.99%
1244.HK 3D MEDICINES
3.280
+0.61%
ARTL Artelo Biosciences, Inc.
1.0000
-4.76%
LEXX Lexaria Bioscience Corp.
1.0800
-5.26%
RNAC Cartesian Therapeutics, Inc.
10.57
-15.03%
PYXS Pyxis Oncology, Inc.
1.0700
-10.08%
ENSC Ensysce Biosciences, Inc.
2.1700
-12.15%
SGMT Sagimet Biosciences Inc.
3.2700
-8.91%
PSTV Plus Therapeutics, Inc.
0.4999
-19.41%
AUPH Aurinia Pharmaceuticals Inc.
8.12
-1.69%